Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 11;11(2):417. doi: 10.3390/vaccines11020417

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Erythema incidence and severity in male (M) and female (F) Wistar Han rats immunized intramuscularly (IM) with (a) BNT162b2 V8 (100 µg), (b) BNT162b2 V9 (30 µg), (c) BNT162b3 (30 µg), and (d) BNT162b1 (30 µg or 100 µg) or buffer control. Erythema measurements from Dosing Phase Days 2, 3/5 *, 9, 14 *, and 16. * Days 3/5 and 14 are only available for Study 1.

Erythema incidence and severity in male (M) and female (F) Wistar Han rats immunized intramuscularly (IM) with (a) BNT162b2 V8 (100 µg), (b) BNT162b2 V9 (30 µg), (c) BNT162b3 (30 µg), and (d) BNT162b1 (30 µg or 100 µg) or buffer control. Erythema measurements from Dosing Phase Days 2, 3/5 *, 9, 14 *, and 16. * Days 3/5 and 14 are only available for Study 1.